Cash Flow from Financial Activities (Quarterly)

Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.

Halozyme Therapeutics, Inc. (HALO) had Cash Flow from Financial Activities of $-3.32M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$264.86M
Net Income	$118.09M
Cost of Goods Sold	$48.40M
Gross Profit	$216.46M
Operating Expenses	$123.33M
Operating Income	$141.53M
Non-Operating Income/Expense	$2.29M
Pre-Tax Income	$143.83M
Normalized Pre-Tax Income	$143.83M
Income after Taxes	$118.09M
Income from Continuous Operations	$118.09M
Consolidated Net Income/Loss	$118.09M
Normalized Income after Taxes	$118.09M
EBIT	$141.53M
EBITDA	$162.12M
Weighted-Average Shares Outstanding (Basic)	123.22M
Weighted-Average Shares Outstanding (Diluted)	126.64M
Earnings per Share (EPS) (Basic)	$0.96
Earnings per Share (EPS) (Diluted)	$0.93
Balance Sheet Financials
Current Assets	$1.26B
Property, Plant, and Equipment	$72.82M
Long-Term Assets	$934.50M
Total Assets	$2.20B
Current Liabilities	$150.38M
Long-Term Debt	$1.51B
Long-Term Liabilities	$1.56B
Total Liabilities	$1.71B
Common Equity	$482.27M
Tangible Shareholders Equity	$-318.62M
Shareholders Equity	$482.27M
Common Shares Outstanding	123.17M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$154.22M
Cash Flow from Investing Activities	$-90.42M
Cash Flow from Financial Activities	$-3.32M
Beginning Cash	$115.85M
End Cash	$176.33M
Increase/Decrease in Cash	$60.48M
Stock-Based Compensation	$10.67M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	8.39
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.76
Debt to Equity Ratio	3.13
Gross Margin	81.73%
Operating Margin	53.44%
EBIT Margin	53.44%
EBITDA Margin	--
Pre-Tax Profit Margin	54.30%
Profit Margin	44.59%
Free Cash Flow	$153.27M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.12
Inventory Turnover	0.29
Receiveable Turnover	0.87
Days Sales in Receivables	103.51
Return on Equity	24.49%
Return on Tangible Equity	-37.06%
Return on Assets	5.38%
Return on Investments	5.94%
Book Value Per Share	$3.92
Free Cash Flow per Share	$1.21
Operating Cash Flow per Share	$1.22

Data from Zacks Investment Research, Inc.